US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Provident

20.92

+0.04000.19%

Post-market: 20.920.00000.00%17:30 EDT

Volume:721.35K

Turnover:15.05M

Market Cap:2.73B

PE:9.38

High:20.97

Open:20.74

Low:20.64

Close:20.88

52wk High:23.98

52wk Low:14.34

Shares:130.62M

Float Shares:126.13M

Volume Ratio:0.56

T/O Rate:0.57%

Dividend:0.96

Dividend Rate:4.59%

EPS(TTM):2.23

EPS(LYR):2.23

ROE:10.72%

ROA:1.19%

PB:0.96

PE(LYR):9.37

Loading ...

Overview Company News Filings

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Cal-Maine Foods And 2 Top Dividend Stocks To Enhance Your Portfolio

Simply Wall St.

Press Release: Emerita Awards Pre-Feasibility Study Contract for the Iberian Belt West Project to SLR Consulting

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

3 Reliable Dividend Stocks To Consider With Up To 9.9% Yield

Simply Wall St.

3 Dividend Stocks To Consider With Up To 3.6% Yield

Simply Wall St.

Provident Bank and The Provident Bank Foundation Launch Crisis Response Fund to Address Food Insecurity

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Press Release: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ASX Runners of the Week: Alvo, 3D Energi, Zuleika & McLaren

The West Australian

Top Three Dividend Stocks To Consider For Your Portfolio

Simply Wall St.

Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PFS/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":20.92,"timestamp":1774555200000,"preClose":20.88,"halted":0,"volume":721351,"hourTrading":{"tag":"盘后","latestPrice":20.92,"preClose":20.92,"latestTime":"17:30 EDT","volume":121526,"amount":2542323.9200000004,"timestamp":1774560638462,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0019157088122606658,"floatShares":126131374,"shares":130622384,"eps":2.229999,"marketStatus":"Post-Mkt","change":0.04,"latestTime":"03-26 18:42:44 EDT","open":20.74,"high":20.965,"low":20.6358,"amount":15054670.390504,"amplitude":0.015766,"askPrice":21.33,"askSize":93,"bidPrice":20.58,"bidSize":121,"shortable":3,"etf":0,"ttmEps":2.229999,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774569600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":20.88,"dividendRate":0.045889,"preHourTrading":{"tag":"盘前","latestPrice":20.61,"preClose":20.88,"latestTime":"09:29 EDT","volume":115,"amount":2372.700125,"timestamp":1774531747826,"change":-0.27,"changeRate":-0.012931,"amplitude":0.008142},"postHourTrading":{"tag":"盘后","latestPrice":20.92,"preClose":20.92,"latestTime":"17:30 EDT","volume":121526,"amount":2542323.9200000004,"timestamp":1774560638462,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.558606,"impliedVol":0.396,"impliedVolPercentile":0.7888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126131374,"roa":"1.19%","roe":"10.72%","lyrEps":2.231753,"volumeRatio":0.558606,"shares":130622384,"dividePrice":0.96,"high":20.965,"amplitude":0.015766,"preClose":20.88,"low":20.6358,"week52Low":14.335,"pbRate":"0.96","psRate":"3.15","week52High":23.9789,"institutionHeld":0.7226,"latestPrice":20.92,"committee":0.130841,"eps":2.229999,"divideRate":0.045889,"volume":721351,"delay":0,"ttmEps":2.229999,"open":20.74,"prevYearClose":19.75,"prevWeekClose":20.29,"prevMonthClose":21.04,"prevQuarterClose":19.75,"fiveDayClose":20.27,"twentyDayClose":22.15,"sixtyDayClose":20.25,"dividendPayoutRate":0.4301551291742411,"dividendFrequency":"Q","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.047123599311239044},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2026-02-13","symbol":"PFS","amount":0.24,"announcedDate":"2026-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-13","defaultRemindTime":1770993000000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-27","payableDate":"2026-02-13","currency":"USD","dateTimestamp":1770958800000,"payDate":"2026-02-27"},{"market":"US","date":"2026-01-27","symbol":"PFS","fiscalQuarterEnding":"2025/12","expectedEps":0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1769490000000,"reportTimeType":"post","actualEps":0.64},{"date":"2025-11-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-10-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-14","defaultRemindTime":1763130600000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-14","currency":"USD","dateTimestamp":1763096400000,"payDate":"2025-11-28"},{"market":"US","date":"2025-10-29","symbol":"PFS","fiscalQuarterEnding":"2025/09","expectedEps":0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1761710400000,"reportTimeType":"post","actualEps":0.55},{"date":"2025-08-15","symbol":"PFS","amount":0.24,"announcedDate":"2025-07-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-15","defaultRemindTime":1755264600000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-29","payableDate":"2025-08-15","currency":"USD","dateTimestamp":1755230400000,"payDate":"2025-08-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"},{"executeDate":"2016-08-11","recordDate":"2016-08-15","paymentDate":"2016-08-31","value":0.18,"currency":"USD"},{"executeDate":"2016-11-10","recordDate":"2016-11-15","paymentDate":"2016-11-30","value":0.18,"currency":"USD"},{"executeDate":"2017-02-13","recordDate":"2017-02-15","paymentDate":"2017-02-28","value":0.19,"currency":"USD"},{"executeDate":"2017-05-11","recordDate":"2017-05-15","paymentDate":"2017-05-31","value":0.19,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.6,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1771992000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2026-03-25","current":9.38117,"percent":0.234964,"low":6.410614,"twenty":8.984755,"median":10.562822,"eighty":15.541087,"high":33.979783,"avg":13.045177,"sd":6.392081,"marketCap":2723710600},"quantilePoints":[{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":15.595237,"twenty":8.579877,"median":10.368229,"eighty":12.928956,"marketCap":1870555147},{"date":"2024-06-07","current":14.804645,"twenty":8.579877,"median":10.368229,"eighty":12.944965,"marketCap":1775728393},{"date":"2024-06-14","current":14.479745,"twenty":8.579877,"median":10.368229,"eighty":12.974084,"marketCap":1736758494},{"date":"2024-06-21","current":14.609705,"twenty":8.578848,"median":10.365511,"eighty":13.001042,"marketCap":1752346453},{"date":"2024-06-28","current":15.541087,"twenty":8.578848,"median":10.365511,"eighty":13.028149,"marketCap":1864060164},{"date":"2024-07-05","current":15.400297,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":1847173207},{"date":"2024-07-12","current":17.403852,"twenty":8.578848,"median":10.365511,"eighty":13.034632,"marketCap":2087487584},{"date":"2024-07-19","current":19.212466,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2304420021},{"date":"2024-07-26","current":32.346496,"twenty":8.578848,"median":10.365511,"eighty":13.039572,"marketCap":2473083727},{"date":"2024-08-02","current":29.436843,"twenty":8.578848,"median":10.365511,"eighty":13.071794,"marketCap":2250623276},{"date":"2024-08-09","current":28.842709,"twenty":8.578848,"median":10.365511,"eighty":13.113823,"marketCap":2205198173},{"date":"2024-08-16","current":30.822445,"twenty":8.578848,"median":10.365511,"eighty":13.134508,"marketCap":2356560887},{"date":"2024-08-23","current":32.631515,"twenty":8.578848,"median":10.365511,"eighty":13.176313,"marketCap":2494875092},{"date":"2024-08-30","current":32.546181,"twenty":8.578848,"median":10.365511,"eighty":13.215944,"marketCap":2488350837},{"date":"2024-09-06","current":31.197913,"twenty":8.578848,"median":10.365511,"eighty":13.228055,"marketCap":2385267609},{"date":"2024-09-13","current":31.300313,"twenty":8.578848,"median":10.365511,"eighty":13.30073,"marketCap":2393096715},{"date":"2024-09-20","current":32.187781,"twenty":8.578848,"median":10.365511,"eighty":13.316627,"marketCap":2460948967},{"date":"2024-09-27","current":31.283246,"twenty":8.578848,"median":10.365511,"eighty":13.405115,"marketCap":2391791864},{"date":"2024-10-04","current":30.429912,"twenty":8.578848,"median":10.365511,"eighty":13.64376,"marketCap":2326549315},{"date":"2024-10-11","current":32.136581,"twenty":8.578848,"median":10.365511,"eighty":13.888037,"marketCap":2457034414},{"date":"2024-10-18","current":33.314182,"twenty":8.578848,"median":10.365511,"eighty":14.144229,"marketCap":2547069132},{"date":"2024-10-25","current":31.88058,"twenty":8.578848,"median":10.365511,"eighty":14.323115,"marketCap":2437461649},{"date":"2024-11-01","current":26.079311,"twenty":8.578848,"median":10.365511,"eighty":14.468915,"marketCap":2459644116},{"date":"2024-11-08","current":29.303632,"twenty":8.578848,"median":10.365511,"eighty":14.501405,"marketCap":2763742765},{"date":"2024-11-15","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.577215,"marketCap":2792450197},{"date":"2024-11-22","current":29.608014,"twenty":8.578848,"median":10.365511,"eighty":14.642195,"marketCap":2792450197},{"date":"2024-11-29","current":29.220619,"twenty":8.578848,"median":10.365511,"eighty":14.720538,"marketCap":2755913466},{"date":"2024-12-06","current":28.72254,"twenty":8.578848,"median":10.365511,"eighty":14.772155,"marketCap":2708937668},{"date":"2024-12-13","current":28.16912,"twenty":8.578848,"median":10.365511,"eighty":14.811522,"marketCap":2656742337},{"date":"2024-12-20","current":26.370502,"twenty":8.578848,"median":10.365511,"eighty":14.879507,"marketCap":2487107512},{"date":"2024-12-27","current":26.107627,"twenty":8.578848,"median":10.365511,"eighty":14.930682,"marketCap":2462314730},{"date":"2025-01-03","current":26.19064,"twenty":8.578848,"median":10.365511,"eighty":15.008136,"marketCap":2470144030},{"date":"2025-01-10","current":24.945443,"twenty":8.578722,"median":10.36461,"eighty":15.045075,"marketCap":2352704535},{"date":"2025-01-17","current":26.730225,"twenty":8.578722,"median":10.36461,"eighty":15.087294,"marketCap":2521034477},{"date":"2025-01-24","current":26.232147,"twenty":8.578722,"median":10.36461,"eighty":15.170193,"marketCap":2474058679},{"date":"2025-01-31","current":20.975271,"twenty":8.578722,"median":10.36461,"eighty":15.27162,"marketCap":2423168232},{"date":"2025-02-07","current":21.686872,"twenty":8.578722,"median":10.36461,"eighty":15.43113,"marketCap":2505375878},{"date":"2025-02-14","current":21.065633,"twenty":8.578722,"median":10.36461,"eighty":15.506431,"marketCap":2433607298},{"date":"2025-02-21","current":20.489576,"twenty":8.578722,"median":10.36461,"eighty":15.601522,"marketCap":2367058251},{"date":"2025-02-28","current":20.614008,"twenty":8.578722,"median":10.36461,"eighty":15.733365,"marketCap":2381433247},{"date":"2025-03-07","current":19.427996,"twenty":8.578596,"median":10.36371,"eighty":15.909803,"marketCap":2244419279},{"date":"2025-03-14","current":19.373214,"twenty":8.58723,"median":10.384564,"eighty":16.110435,"marketCap":2238090520},{"date":"2025-03-21","current":19.113398,"twenty":8.626133,"median":10.390798,"eighty":16.250162,"marketCap":2208075312},{"date":"2025-03-28","current":19.282843,"twenty":8.679674,"median":10.422436,"eighty":16.324736,"marketCap":2227650448},{"date":"2025-04-04","current":17.498022,"twenty":8.697705,"median":10.433885,"eighty":16.538637,"marketCap":2021459018},{"date":"2025-04-11","current":16.594315,"twenty":8.729831,"median":10.450581,"eighty":16.720339,"marketCap":1917058294},{"date":"2025-04-17","current":17.498022,"twenty":8.74788,"median":10.472646,"eighty":16.838352,"marketCap":2021459018},{"date":"2025-04-25","current":14.654875,"twenty":8.784492,"median":10.48224,"eighty":16.926427,"marketCap":2161169063},{"date":"2025-05-02","current":15.142189,"twenty":8.798752,"median":10.513034,"eighty":16.926427,"marketCap":2233033814},{"date":"2025-05-09","current":15.159534,"twenty":8.804878,"median":10.526765,"eighty":16.926427,"marketCap":2235591607},{"date":"2025-05-16","current":15.505075,"twenty":8.82909,"median":10.533858,"eighty":16.926427,"marketCap":2286548985},{"date":"2025-05-23","current":14.787412,"twenty":8.855843,"median":10.556785,"eighty":16.926427,"marketCap":2180714431},{"date":"2025-05-30","current":14.884872,"twenty":8.8606,"median":10.572534,"eighty":16.926427,"marketCap":2195087025},{"date":"2025-06-06","current":14.619071,"twenty":8.875633,"median":10.60779,"eighty":16.926427,"marketCap":2155889043},{"date":"2025-06-13","current":15.000053,"twenty":8.887975,"median":10.619572,"eighty":16.926427,"marketCap":2212072818},{"date":"2025-06-20","current":14.30011,"twenty":8.911603,"median":10.626285,"eighty":16.928687,"marketCap":2108851463},{"date":"2025-06-27","current":15.850617,"twenty":8.946056,"median":10.641658,"eighty":16.928687,"marketCap":2337506362},{"date":"2025-07-03","current":16.710041,"twenty":8.946056,"median":10.65175,"eighty":16.928687,"marketCap":2464246506},{"date":"2025-07-11","current":16.648021,"twenty":8.954399,"median":10.683931,"eighty":16.928687,"marketCap":2455100310},{"date":"2025-07-18","current":16.4974,"twenty":8.954399,"median":10.718159,"eighty":16.928687,"marketCap":2432888120},{"date":"2025-07-25","current":10.379214,"twenty":8.954399,"median":10.725223,"eighty":16.928687,"marketCap":2396954859},{"date":"2025-08-01","current":10.305683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2379973707},{"date":"2025-08-08","current":10.124683,"twenty":8.954399,"median":10.733069,"eighty":16.928687,"marketCap":2338173949},{"date":"2025-08-15","current":10.899581,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2517127428},{"date":"2025-08-22","current":10.633738,"twenty":8.954399,"median":10.730998,"eighty":16.928687,"marketCap":2455734076},{"date":"2025-08-29","current":11.255924,"twenty":8.954399,"median":10.756738,"eighty":16.928687,"marketCap":2599420644},{"date":"2025-09-05","current":11.380362,"twenty":8.954068,"median":10.786944,"eighty":16.930946,"marketCap":2628157958},{"date":"2025-09-12","current":11.312487,"twenty":8.954399,"median":10.806309,"eighty":16.928687,"marketCap":2612483060},{"date":"2025-09-19","current":11.493487,"twenty":8.954399,"median":10.823106,"eighty":16.928687,"marketCap":2654282788},{"date":"2025-09-26","current":11.0523,"twenty":8.984755,"median":10.848771,"eighty":16.928687,"marketCap":2552395949},{"date":"2025-10-03","current":11.018362,"twenty":8.984755,"median":10.865282,"eighty":16.928687,"marketCap":2544558500},{"date":"2025-10-10","current":10.876956,"twenty":8.984755,"median":10.902195,"eighty":16.928687,"marketCap":2511902462},{"date":"2025-10-17","current":10.113363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2335559855},{"date":"2025-10-24","current":10.475363,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2419159313},{"date":"2025-10-31","current":9.425046,"twenty":8.984755,"median":10.905022,"eighty":16.928687,"marketCap":2415196286},{"date":"2025-11-07","current":9.328196,"twenty":8.984755,"median":10.888266,"eighty":16.928687,"marketCap":2390378153},{"date":"2025-11-14","current":9.557624,"twenty":8.984755,"median":10.857,"eighty":16.928687,"marketCap":2449169700},{"date":"2025-11-21","current":9.205903,"twenty":8.984755,"median":10.840069,"eighty":16.928687,"marketCap":2359040255},{"date":"2025-11-28","current":9.812493,"twenty":8.984755,"median":10.820894,"eighty":16.928687,"marketCap":2514480892},{"date":"2025-12-05","current":10.210091,"twenty":8.984755,"median":10.806309,"eighty":16.928687,"marketCap":2616366351},{"date":"2025-12-12","current":10.628077,"twenty":8.984755,"median":10.780942,"eighty":16.928687,"marketCap":2723476706},{"date":"2025-12-19","current":10.801389,"twenty":8.984755,"median":10.756738,"eighty":16.928687,"marketCap":2767888316},{"date":"2025-12-26","current":10.444571,"twenty":8.984755,"median":10.741206,"eighty":16.928687,"marketCap":2676452648},{"date":"2026-01-02","current":10.067363,"twenty":8.984755,"median":10.729963,"eighty":16.928687,"marketCap":2579792084},{"date":"2026-01-09","current":10.3885,"twenty":8.984755,"median":10.718159,"eighty":16.685233,"marketCap":2662084185},{"date":"2026-01-16","current":10.342623,"twenty":8.984755,"median":10.6903,"eighty":16.559093,"marketCap":2650328171},{"date":"2026-01-23","current":10.862558,"twenty":8.984755,"median":10.681432,"eighty":16.43782,"marketCap":2783563003},{"date":"2026-01-30","current":9.968317,"twenty":8.984755,"median":10.656886,"eighty":16.315692,"marketCap":2902375266},{"date":"2026-02-06","current":10.569467,"twenty":8.984755,"median":10.64505,"eighty":16.315692,"marketCap":3077405998},{"date":"2026-02-13","current":10.309268,"twenty":8.984755,"median":10.637462,"eighty":16.315692,"marketCap":3001646428},{"date":"2026-02-20","current":10.295809,"twenty":8.984755,"median":10.627766,"eighty":16.315692,"marketCap":2997727829},{"date":"2026-02-27","current":9.936914,"twenty":8.984755,"median":10.621728,"eighty":16.286003,"marketCap":2893231870},{"date":"2026-03-06","current":9.538728,"twenty":8.984755,"median":10.611113,"eighty":16.080978,"marketCap":2777296077},{"date":"2026-03-13","current":9.157179,"twenty":8.984755,"median":10.607786,"eighty":15.806317,"marketCap":2666204234},{"date":"2026-03-20","current":9.098824,"twenty":8.984755,"median":10.569303,"eighty":15.687592,"marketCap":2649213717},{"date":"2026-03-25","current":9.354687,"twenty":8.984755,"median":10.562822,"eighty":15.541087,"marketCap":2723710600}],"updateTime":1774564324126},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589354927","title":"Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354927","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354927?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:30","pubTimestamp":1765207800,"startTime":"0","endTime":"0","summary":"Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","OS","BK4139","PFS","BK4568","BK4097","CRVS","LU2463526074.USD","BK4195","BK4211","ASH"],"gpt_icon":0},{"id":"2589802971","title":"RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802971","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802971?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:00","pubTimestamp":1765155600,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinibamong Asian patients.Results from 501 participants who self-identified as Asian in the MARIPOSA trial, showed those treated with amivantamab plus lazertinib had a 26 percent lower risk of death compared with osimertinib , based on a median follow-up of 38.7 months. MedianOSfor the combination was not yet reached compared with 38.4months for osimertinib . Survival projections suggest that amivantamab plus lazertinib could extend median OS to more than a year beyond that achieved with osimertinib. At three years, 61 percent of patients treated with the combination were alive compared with 53 percent of those receiving osimertinib. The survival advantage was maintained at 42 months, with survival rates of 59 percent and 46 percent,respec","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2771572/1298d71d_502d_4bb1_9019_512d4a14e9a7_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-delivers-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-benefit-for-asian-patients-with-egfr-mutated-non-small-cell-lung-cancer-in-the--302633939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930813.SGD","LU2089984988.USD","IE00BGHQF631.EUR","IE00BLSP4452.SGD","LU1674673691.USD","LU1066051225.USD","LU1894683348.USD","BK4585","IE00B4R5TH58.HKD","IE00B3PB1722.GBP","BK4581","LU2505996681.GBP","LU1732799900.SGD","LU0912757837.SGD","BK4550","LU0345769631.USD","LU1162221912.USD","IE00B3T34201.USD","LU0345770308.USD","LU2602419157.SGD","LU1261432733.SGD","BK7095","IE00B19Z3B42.SGD","LU1929549753.HKD","LU2592432038.USD","JNJ","LU1778281490.HKD","LU1074936037.SGD","BK4534","LU0466842654.USD","LU0234572021.USD","LU2468319806.SGD","LU0058720904.USD","OS","LU2129689514.USD","LU0098860793.USD","IE00B19Z3581.USD","BK4504","LU0345770993.USD","BK4195","LU2505996509.AUD","PFS","ORR","LU0203347892.USD","ORR.AU","IE00B1BXHZ80.USD","SEER","IE00BJT1NW94.SGD","BK4559","LU2129689431.USD"],"gpt_icon":0},{"id":"2589877324","title":"ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877324","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589877324?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:00","pubTimestamp":1765112400,"startTime":"0","endTime":"0","summary":"- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an appr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201128/0/en/ALX-Oncology-Announces-Positive-Results-from-Ongoing-Investigator-Sponsored-Phase-2-Trial-Evaluating-Evorpacept-in-Combination-with-Standard-of-Care-Treatment-in-Patients-with-Indo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMP","BK4211","BK4109","ALX","OS","BK4080","BK4124","LU2463526074.USD","BK4161","CR","BK4195","PFS","PR","ORR","BK4213","BK4231","BK4097","ASH"],"gpt_icon":0},{"id":"2589187279","title":"Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589187279","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589187279?lang=en_us&edition=fundamental","pubTime":"2025-12-07 20:50","pubTimestamp":1765111800,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201123/0/en/Genmab-Presents-Pivotal-Phase-3-Data-from-EPCORE-FL-1-Trial-Demonstrating-Clinical-Benefit-of-EPKINLY-epcoritamab-bysp-in-Combination-with-Rituximab-and-Lenalidomide-R2-in-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU2463526074.USD","BK4211","BK4195","ASH","PFS","BK4109","CR","ORR"],"gpt_icon":0},{"id":"2589261588","title":"Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261588?lang=en_us&edition=fundamental","pubTime":"2025-12-06 22:30","pubTimestamp":1765031400,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201065/0/en/Genmab-Announces-Data-From-Multiple-Clinical-Trials-Showing-Treatment-with-Fixed-Duration-Epcoritamab-Led-to-Remissions-in-First-Line-Diffuse-Large-B-Cell-Lymphoma-DLBCL-and-Follic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OS","BK4548","BK4097","BK4585","IE0009354923.USD","LU1228905540.USD","IE00B7SZL793.SGD","IPI","BK4006","BK4106","BK4211","BK4195","LU0545562505.USD","BK4588","LU0390134368.USD","BK4109","LU2065731478.USD","CR","IE0034235188.USD","ASH","IE00B19Z4B17.USD","IE0031619046.USD","LU0963586101.USD","BK4093","BR","IE00B66KJ199.SGD","LU1228905037.USD","ORR","BK4161","CRS","PFS","BK4226","BK4187","LU2463526074.USD"],"gpt_icon":0},{"id":"2589841767","title":"Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2589841767","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589841767?lang=en_us&edition=fundamental","pubTime":"2025-12-06 11:11","pubTimestamp":1764990660,"startTime":"0","endTime":"0","summary":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mO","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/06/3201030/0/en/Toripalimab-Presents-Long-Term-Survival-Benefits-as-1st-line-Treatment-for-Advanced-Nasopharyngeal-Carcinoma-and-Esophageal-Squamous-Cell-Carcinoma-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","IE00B19Z4B17.USD","PFS","AEIS","BK4195","BK4161","ORR","IE00B7SZL793.SGD","LU0053671581.USD","LU0757428866.USD","IE00B66KJ199.SGD","BK4211","OS","RCC","GP","BK4149","HCC","ITT","IE0031619046.USD","LU1815336091.USD","LU0054578231.USD","BK4006","BK4097"],"gpt_icon":0},{"id":"2589811076","title":"Cal-Maine Foods And 2 Top Dividend Stocks To Enhance Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2589811076","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589811076?lang=en_us&edition=fundamental","pubTime":"2025-12-06 01:01","pubTimestamp":1764954109,"startTime":"0","endTime":"0","summary":"As U.S. stock indexes experience modest gains following key inflation data, investors are closely watching the Federal Reserve's upcoming policy decisions and major corporate moves like Netflix's acquisition of Warner Bros. Discovery. In this dynamic market environment, dividend stocks such as Cal-Maine Foods can offer a reliable income stream and potential stability, making them an attractive option for those looking to enhance their portfolios amidst economic fluctuations.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nasdaq-ctbi/community-trust-bancorp/news/cal-maine-foods-and-2-top-dividend-stocks-to-enhance-your-po","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nasdaq-ctbi/community-trust-bancorp/news/cal-maine-foods-and-2-top-dividend-stocks-to-enhance-your-po","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NBHC","LU0772969993.USD","PEBO","LU0321505439.SGD","COLB","BK4588","BK4212","LU1481011911.USD","BK4211","BK4585","BK4009","FMNB","LU0566484027.USD","EBF","LU0731783394.SGD","CTBI","LU1509826696.USD","BK4195","PFS","BK4112","HTBK","CALM","OTCM","CZNC","LU1559883803.SGD","LU0731783048.USD","LU1599440770.SGD","OMC","LU0321505868.SGD","FIBK","BK4087","LU1481011671.HKD","LU0742537680.HKD"],"gpt_icon":0},{"id":"2588043035","title":"Press Release: Emerita Awards Pre-Feasibility Study Contract for the Iberian Belt West Project to SLR Consulting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043035","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043035?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:04","pubTimestamp":1764763440,"startTime":"0","endTime":"0","summary":"TORONTO, Dec. 03, 2025  -- Emerita Resources Corp.   is pleased to announce it has awarded the contract for completion of the Iberian Belt West  Pre-Feasibility Study  to SLR Consulting Limited  . The PFS will be designed to meet NI 43-101 requirements. Wardell Armstrong, which was acquired by SLR in October 2024, has been the Qualified Person  responsible for the Mineral Resource Estimates to date at IBW and have been extensively involved in IBW metallurgical testing. SLR was awarded this engagement after a diligent tendering process. The initial group of twenty-three companies were narrowed down to a short list of five, from which detailed proposals were considered. The SLR proposal provided the best fit in terms of timing, expertise familiarity with the IBW project and other projects in the region and overall value. The PFS is expected to be completed in approximately six months.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4168","EMOTF","PFS","BK4195"],"gpt_icon":0},{"id":"2588045492","title":"Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045492?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:01","pubTimestamp":1764763260,"startTime":"0","endTime":"0","summary":"Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3198744/0/en/Black-Diamond-Therapeutics-Announces-Preliminary-Phase-2-Data-for-Silevertinib-in-1L-NSCLC-and-Plans-for-a-Phase-2-Trial-of-Silevertinib-in-GBM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","OS","BK4139","BDTX","BK4097","PFS"],"gpt_icon":0},{"id":"2588055274","title":"PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055274","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055274?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:30","pubTimestamp":1764682200,"startTime":"0","endTime":"0","summary":"Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval PathwayPRINCETON, N.J., Dec.  02, 2025  (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197934/37149/en/PDS-Biotech-Announces-Scheduling-of-Type-C-Meeting-with-U-S-Food-and-Drug-Administration-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4092","PFS","BK4080","BK4211","PDS","BK4231","ADC"],"gpt_icon":0},{"id":"2588058732","title":"BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058732","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058732?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:30","pubTimestamp":1764678600,"startTime":"0","endTime":"0","summary":"Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3197795/0/en/BriaCell-to-Present-Phase-2-Survival-Phase-3-Clinical-Data-at-SABCS-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTH","BK4139","NLR","CPI","PFS","BK4606","BCTX","BK4211","BK4195"],"gpt_icon":0},{"id":"2588809037","title":"3 Reliable Dividend Stocks To Consider With Up To 9.9% Yield","url":"https://stock-news.laohu8.com/highlight/detail?id=2588809037","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588809037?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:01","pubTimestamp":1764673302,"startTime":"0","endTime":"0","summary":"As the U.S. stock market faces a downturn with major indices like the Dow Jones and S&P 500 closing lower amid risk-off sentiment, investors are increasingly seeking stability through dividend stocks. In this environment, reliable dividend-paying companies can offer a steady income stream, making them an attractive option for those looking to balance their portfolios against market volatility.","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/296527-main-header/1756218147399","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/296527-main-header/1756218147399"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/energy/nyse-cop/conocophillips/news/3-reliable-dividend-stocks-to-consider-with-up-to-99-yield","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/energy/nyse-cop/conocophillips/news/3-reliable-dividend-stocks-to-consider-with-up-to-99-yield","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EBF","BK4588","YRD","LU0868494617.USD","COP","LU0256863811.USD","OTCM","LU1988902786.USD","LU0788109394.HKD","HTBK","LU0477156953.USD","LU1074936037.SGD","LU0566484027.USD","LU0314106906.USD","LU0345780950.USD","BK4213","LU1064131342.USD","IE00BGHQF524.EUR","LU0130102774.USD","LU0130517989.USD","LU0957791311.USD","BK4585","LU1201861249.SGD","PFS","COLB","CPF","LU2125154935.USD","FMNB","LU0300736062.USD","PEBO","BLX.AU","CZNC","LU0648001328.SGD","BLX","IE00B2Q91V27.USD","FIBK","LU0648000940.SGD","LU0300736492.USD","LU0122376428.USD","LU0345781412.USD","LU1815333072.USD","LU0980610538.SGD","IE00B3CCJ963.GBP","LU2125154778.USD","BK4164","LU0868494708.USD","LU0792757196.USD","LU0456854461.SGD","BK4166","BK4112"],"gpt_icon":0},{"id":"2586617212","title":"3 Dividend Stocks To Consider With Up To 3.6% Yield","url":"https://stock-news.laohu8.com/highlight/detail?id=2586617212","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586617212?lang=en_us&edition=fundamental","pubTime":"2025-11-27 01:01","pubTimestamp":1764176516,"startTime":"0","endTime":"0","summary":"As the U.S. stock market experiences a notable upswing, with major indices like the Dow Jones, S&P 500, and Nasdaq showing significant gains entering the Thanksgiving holiday, investors are increasingly eyeing opportunities for stable income amid this positive momentum. In such an environment, dividend stocks can offer a reliable source of income through regular payouts while potentially benefiting from capital appreciation as markets rise.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3071000-choice2-main-header/1585186751359","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3071000-choice2-main-header/1585186751359"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-plow/douglas-dynamics/news/3-dividend-stocks-to-consider-with-up-to-36-yield","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-plow/douglas-dynamics/news/3-dividend-stocks-to-consider-with-up-to-36-yield","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BANR","CZNC","LU0477156797.USD","PEBO","WEYS","LU0648000940.SGD","BK4211","BK4009","FIBK","EBF","LU1201861165.SGD","US2Y.BOND","US3Y.BOND","HTBK","PLOW","IPG.AU","FMNB","TLTW","BK4159","TMF","COLB","US30Y.BOND","LU0130103400.USD","OTCM","PFS","BK4112","US7Y.BOND","LU0566484027.USD","US12M.BOND","BK7031","BK4588","BK4087","BK4585","US10Y.BOND","US5Y.BOND","BK4149","LU1559883803.SGD","US6M.BOND","BK4195","LU0130518102.USD","IPG"],"gpt_icon":1},{"id":"2586403117","title":"Provident Bank and The Provident Bank Foundation Launch Crisis Response Fund to Address Food Insecurity","url":"https://stock-news.laohu8.com/highlight/detail?id=2586403117","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586403117?lang=en_us&edition=fundamental","pubTime":"2025-11-26 02:30","pubTimestamp":1764095400,"startTime":"0","endTime":"0","summary":"The fund will provide targeted relief to nonprofit organizations on the front lines of food access amid rising demandISELIN, N.J., Nov.  25, 2025  (GLOBE NEWSWIRE) -- Provident Bank, a leading New Jer","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194648/0/en/Provident-Bank-and-The-Provident-Bank-Foundation-Launch-Crisis-Response-Fund-to-Address-Food-Insecurity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4138","PBF","PFS","BK4195","BK4588","BK4585"],"gpt_icon":0},{"id":"2586441294","title":"Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2586441294","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586441294?lang=en_us&edition=fundamental","pubTime":"2025-11-25 14:15","pubTimestamp":1764051300,"startTime":"0","endTime":"0","summary":"Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings off","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194022/0/en/Novartis-data-underscore-pioneering-scientific-innovation-in-Hematology-and-Oncology-at-ASH-and-SABCS.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4561","ET","LU2463526074.USD","BK4109","BK4097","BK4588","EBC","DDFS","ASH","BK4211","BK4195","BK4144","BK4190","IS","BK4585","PFS","ASC","OS","FUL","BC","ITP","BK4199","BK4581"],"gpt_icon":0},{"id":"2585658461","title":"Press Release: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2585658461","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585658461?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:00","pubTimestamp":1763985600,"startTime":"0","endTime":"0","summary":"- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -. - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 -. - Management to host conference call today, November 24 , at 8:30 am EST -. TEL AVIV, Israel, Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd.  , a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.\"At the same time, the ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer, which is being led by Columbia University and supported by both Regeneron and BioLineRx, continues to progress, giving us a second opportunity to leverage our drug development expertise to bring true innovation to patients with difficult-to-treat cancers,\" Mr. Se","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCD","LU1093756325.SGD","MTD","PFS","LU0347712357.USD","BK4139","BK4548","LU2413666426.HKD","LU1721428933.USD","BK4567","BK4195","BK4588","BK4585","IE00B64QTZ34.USD","IE00BLDYK493.USD","LU2211817866.USD","BK4533","IE00BFXG0V08.USD","BK4121","LU2413666699.HKD","BLRX","BK4211","BK4109","IE00BYQQ9H92.USD","LU2463526074.USD","ASH","LU1093756168.USD","PB"],"gpt_icon":0},{"id":"2585419275","title":"ASX Runners of the Week: Alvo, 3D Energi, Zuleika & McLaren","url":"https://stock-news.laohu8.com/highlight/detail?id=2585419275","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585419275?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:02","pubTimestamp":1763679734,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Alvo Minerals, which put the first-ever diamond hole into its Brazilian copper project only to pull out 13m of fat visual copper sulphides just 40m from surface. ","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-20752009/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-20752009/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/this-weeks-bulls-n-bears-asx-runner-of-the-week-is-alvo-minerals-c-20752009","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/this-weeks-bulls-n-bears-asx-runner-of-the-week-is-alvo-minerals-c-20752009","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["TDO.AU","BK7104","BK7506","BK4211","BK7095","PFS","ZAG.AU","XJO.AU","BK4195","ALV.AU","BK7142","XAO.AU","XKO.AU","MML.AU"],"gpt_icon":0},{"id":"2585152403","title":"Top Three Dividend Stocks To Consider For Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2585152403","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585152403?lang=en_us&edition=fundamental","pubTime":"2025-11-21 01:02","pubTimestamp":1763658126,"startTime":"0","endTime":"0","summary":"In the current U.S. market landscape, major stock indexes have recently pared gains following impressive earnings reports from tech giants like Nvidia, while economic indicators such as job growth and Treasury yields continue to influence investor sentiment. Amidst these dynamic conditions, dividend stocks can offer a reliable income stream and potential stability for portfolios, particularly when navigating fluctuating market environments.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/banks/nasdaq-fult/fulton-financial/news/top-three-dividend-stocks-to-consider-for-your-portfolio-12","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/banks/nasdaq-fult/fulton-financial/news/top-three-dividend-stocks-to-consider-for-your-portfolio-12","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","FMNB","LU0566484027.USD","PFBC","BK4588","US6M.BOND","BK4009","US12M.BOND","FIBK","BK7031","OTCM","BK4087","EBF","PEBO","TLTW","PFS","COLB","IPG","US10Y.BOND","TMF","LU0130518102.USD","BK4211","US3Y.BOND","HTBK","US7Y.BOND","LU0648000940.SGD","LKFN","BK4195","LU1559883803.SGD","US30Y.BOND","LU0130103400.USD","BK4112","CZNC","US2Y.BOND","FULT","LU0477156797.USD","IPG.AU","LU1201861165.SGD","US5Y.BOND"],"gpt_icon":1},{"id":"2584957554","title":"Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957554","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584957554?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:58","pubTimestamp":1763488680,"startTime":"0","endTime":"0","summary":"Genmab's Epkinly receives traditional FDA approval for relapsed or refractory follicular lymphoma in combination and monotherapy. Clinical trial data show superior results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/18/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/18/Cancer-research.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/48931917/major-victory-for-genmab-as-epkinly-receives-fda-approval-for-type-of-pretreated-blood-cancer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/48931917/major-victory-for-genmab-as-epkinly-receives-fda-approval-for-type-of-pretreated-blood-cancer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4211","BK4161","BK4201","BK4195","CR","EC","GMAB","ORR","PFS","BK4139"],"gpt_icon":0},{"id":"2584543559","title":"Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584543559","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584543559?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:30","pubTimestamp":1763483400,"startTime":"0","endTime":"0","summary":"Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line settingIn the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/18/3190331/0/en/Genmab-Announces-EPKINLY-epcoritamab-bysp-in-Combination-with-Rituximab-and-Lenalidomide-Approved-by-the-U-S-Food-and-Drug-Administration-for-the-Treatment-of-Relapsed-or-Refractor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","CRS","LU2065731478.USD","CR","BK4211","IE0031619046.USD","LU0963586101.USD","IE00B19Z4B17.USD","BK4187","ORR","BK4006","IE00B7SZL793.SGD","PFS","BK4195","IE00B66KJ199.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":199,"code":"91000000","status":"200"}]}}